A Deeper Dive: Patient Perceptions of Burden and Satisfaction with Current and Emerging Psoriatic Therapies
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s815
DOI: 10.25251/b5jxq542 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Alice B Gottlieb und 8 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction:Current and emerging systemic therapies are expanding treatment options for moderate-to-severe plaque psoriasis. Real-world usage, however, is influenced by patient-perceived treatment burden. Here, results from the 2026 cross-sectional Systemic Perceptions Survey of the National Psoriasis Foundation patient community are reported. Materials and Methods: Adults aged ≥21 years who self-reported clinician diagnosed moderate-to-severe plaque psoriasis with possible concomitant psoriatic arthritis and a prescription for psoriasis therapy within the past 12 months were included. Treatment burden and preference were assessed.
Results
Among 270 participants, 54.8% had psoriasis only and 45.2% had concomitant psoriatic arthritis. Patients on biologics reported higher satisfaction with disease control (94%) compared to oral-only (70%) and topical-only patients (54%). When asked about a biologic that offered greater skin clearance, 69% would try a biologic, 17% preferred an oral medication, and 13% preferred a topical. Patients on biologics rated frequency of use as the least burdensome of all assessed burden dimensions, while those on topicals and orals rated it much higher. A biologic administered once or twice yearly with a high chance of disease clearance was the preferred treatment option for 68% of patients, compared to daily orals (22%) and topicals (10%). Patients preferred fixed-dosing intervals (76%) over as-needed dosing (24%). Additionally, 61% defined “remission” as sustained clear skin while on treatment, suggesting patients are not expecting to come off therapy.
Conclusion
Patient preferences extend beyond route of administration, with many favoring long-interval biologics when infrequent dosing and high clearance are considered. These findings highlight the importance of balancing treatment burden alongside efficacy and patient expectations for on-treatment remission.
Zitieren
APA
Gottlieb, A. B., Armstrong, A. W., Levi, E., Jardon, S., Lau, G., Sweeney, C., O'Neal, A. L., Eakin, G. S., & Blauvelt, A. (2026). A Deeper Dive: Patient Perceptions of Burden and Satisfaction with Current and Emerging Psoriatic Therapies. SKIN The Journal of Cutaneous Medicine, 10(6), s815. https://doi.org/10.25251/b5jxq542
Vancouver
Gottlieb AB, Armstrong AW, Levi E, Jardon S, Lau G, Sweeney C, et al. A Deeper Dive: Patient Perceptions of Burden and Satisfaction with Current and Emerging Psoriatic Therapies. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s815. doi:10.25251/b5jxq542
BibTeX
@article{Gottlieb2026,
author = {Gottlieb, Alice B and Armstrong, April W and Levi, Eugenia and Jardon, Shauna and Lau, Gabriel and Sweeney, Colin and O'Neal, Alicia L and Eakin, Guy S and Blauvelt, Andrew},
title = {A Deeper Dive: Patient Perceptions of Burden and Satisfaction with Current and Emerging Psoriatic Therapies},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {s815},
doi = {10.25251/b5jxq542}
}
EUVIMED